# China Neurodegenerative Disease Market

> China Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.6%
- **2024:** $ 6.14 Billion
- **2025:** $ 6.61 Billion
- **2035:** $ 13.76 Billion
- **Key Players:** Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co (US), Amgen (US), Sanofi (FR), Pfizer (US)

**Report ID:** MRFR/MED/50859-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-neurodegenerative-disease-market-52618

---

## Market Summary

## **China Neurodegenerative Disease Market Overview**

As per MRFR analysis, the China Neurodegenerative Disease Market Size was estimated at 1.66 (USD Billion) in 2023. The China Neurodegenerative Disease Market Industry is expected to grow from 1.75(USD Billion) in 2024 to 3.49 (USD Billion) by 2035. The China Neurodegenerative Disease Market CAGR (growth rate) is expected to be around 6.487% during the forecast period (2025 - 2035)

**Key China Neurodegenerative Disease Market Trends Highlighted**

In China, the neurodegenerative disease market is significantly influenced by an aging population, as the country faces a notable increase in age-related health issues. The government has recognized neurodegenerative diseases as a major public health concern, prompting increased funding for research and development. This initiative focuses on conditions such as Alzheimer's disease and Parkinson's disease, which are prevalent in the elderly demographic. The rising prevalence of these disorders is a key market driver, coupled with the growing awareness of early diagnosis and treatment options. 

There are substantial opportunities to be explored in China’s neurodegenerative disease market, particularly in the fields of drug development and innovative therapies.Biopharmaceutical companies are investing in novel therapeutic solutions, while local startups are emerging with unique approaches, driven by advancements in biotechnology and artificial intelligence. Moreover, collaborations between academic institutions and pharmaceutical companies are becoming common, fostering innovation and knowledge sharing. This collaborative environment is essential for addressing the complex challenges posed by neurodegenerative diseases. 

In recent times, there has been a trend towards personalized medicine within this market. With the advancement in genomics and biomarker identification, treatments are becoming more targeted.Additionally, China is seeing a rise in the demand for supportive care services and rehabilitation facilities, which aligns with the broader global trend towards holistic care for patients with neurodegenerative disorders. These trends reflect a comprehensive approach to managing neurodegenerative diseases, illustrating a shift toward patient-centric models that aim to improve quality of life for individuals affected by these conditions. This patient-focused model is expected to drive further growth in the region’s healthcare landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Neurodegenerative Disease Market Drivers**

**Aging Population in China**

The China Neurodegenerative Disease Market Industry is expanding as a result of the country's aging population. According to data from the National Bureau of Statistics, the number of people aged 60 and above is predicted to reach 487 million by 2050, which means that neurological disorders like Parkinson's and Alzheimer's would become more common. According to research, between 6.5% and 16.5% of those 65 and older have Alzheimer's disease, which is in line with the growing number of senior people. 

As a result of the ongoing documentation and investigation of these patterns by reputable institutions such as the Chinese Academy of Medical Sciences, neurodegenerative disorders will likely receive more attention in the future. Additionally, government programs for health and elder care have made it possible to better support research and development for therapies that target neurodegenerative diseases, which has fueled market expansion.

**Rising Awareness and Diagnosis Improvement**

In recent years, there has been an increased awareness of neurodegenerative diseases in China, resulting in improved diagnosis and treatment options within the China Neurodegenerative Disease Market Industry. Reports indicate that awareness campaigns, often led by health organizations such as the China Alzheimer's Disease Association, have increased diagnostic rates significantly. 

This boost is evident from a 30% increase in reported Alzheimer's cases over the last five years due to better screening and public awareness programs.As detection improves, healthcare providers are becoming more aware of the need for intervention and therapeutic options, leading to an expanding market for neurodegenerative treatments and medications.

**Advancements in Biotechnology and Pharmaceuticals**

Advancements in biotechnology and pharmaceuticals are driving innovation in the China Neurodegenerative Disease Market Industry. The increasing number of biotechnology firms and research institutions specializing in regenerative medicine in cities like Beijing and Shanghai showcases a competitive landscape that fosters development. The China National Pharmaceutical Group is one such established organization that invests heavily in the Research and Development of neurodegenerative treatments.

Moreover, the acceleration of clinical trials for novel drug candidates in the field has been evident, with over 50 ongoing trials in China focusing on neurodegenerative diseases according to the Chinese Clinical Trial Registry. Such advancements not only encourage further investment in the market but also lead to the timely delivery of cutting-edge therapies to patients, propelling industry growth.

**China Neurodegenerative Disease Market Segment Insights**

**Neurodegenerative Disease Market Disease Type Insights**

The China Neurodegenerative Disease Market has emerged as a critical focus area within the healthcare sector, particularly considering the growing prevalence of various conditions categorized under Disease Type. The market exhibits considerable segmentation, with conditions like Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Huntington's Disease being particularly significant. Alzheimer's Disease continues to attract attention due to its substantial impact on an aging population, presenting challenges for families and caregivers, thus necessitating innovative treatment solutions and supportive care systems, which the market is working to address. 

On the other hand, Parkinson's Disease, known for its motor symptoms and progressive nature, demands ongoing research for improved neuroprotective therapies, which reflects a strong market trend toward innovative drug development and patient management solutions. Multiple Sclerosis, an autoimmune disorder affecting the central nervous system, is increasingly recognized in China, prompting a need for effective therapies and lifestyle adaptations among the affected population. Meanwhile, Amyotrophic Lateral Sclerosis is gaining significance, as awareness and advocacy for better supportive care and medical advancements continue to evolve. 

Huntington's Disease, though relatively less prevalent, nonetheless poses considerable challenges for affected individuals and their families, driving research into genetic interventions and comprehensive care strategies. Overall, the China Neurodegenerative Disease Market segmentation highlights the importance of tailored medical approaches and the requirement for advancements in both healthcare infrastructure and patient-centered strategies, ensuring that diverse needs across different disease types are adequately addressed. 

The rise in diagnosed cases and ongoing demographic shifts fosters an environment ripe with opportunities for healthcare providers and pharmaceutical companies alike, positioning the market for sustained growth and innovation in combating neurodegenerative diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Neurodegenerative Disease Market Diagnosis Method Insights**

The Diagnosis Method segment within the China Neurodegenerative Disease Market is crucial in determining the presence and extent of such disorders. Neurological Examination plays a vital role, providing clinicians with immediate insights based on clinical symptoms and motor skills assessment. Imaging Techniques, which include Magnetic Resonance Imaging and Computed Tomography, are essential in visualizing brain changes, helping to identify conditions such as Alzheimer's and Parkinson's disease. 

Cerebrospinal Fluid Analysis enables the detection of biomarkers associated with neurodegeneration, offering a critical window into the underlying pathological processes.Electrophysiological Tests, including EEG and EMG, assist in evaluating nerve and brain activity, thereby supporting diagnosis and monitoring. Collectively, these methodologies are integral for accurate diagnosis, which is essential for effective treatment plans and improving patient outcomes in China. The increasing prevalence of neurodegenerative diseases in the aging population further emphasizes the need for innovative and efficient diagnostic approaches in this segment.

As the China Neurodegenerative Disease Market continues to evolve, advancements in these diagnostic methods are expected to enhance the accuracy and speed of neurodegenerative disease identification.

**Neurodegenerative Disease Market Treatment Type Insights**

The China Neurodegenerative Disease Market, particularly in the Treatment Type segment, is poised for significant growth as it encompasses crucial areas like Medication, Therapy, Rehabilitation, and Surgical Interventions. Each of these areas plays an essential role in addressing the complexities of neurodegenerative disorders, which are increasingly prevalent in an aging population.

Medication remains a key player in managing symptoms and improving the quality of life for patients, while Therapy focuses on cognitive and physical improvement strategies that are vital for patient recovery.Rehabilitation not only aids in recovery but also emphasizes the importance of sustaining daily functioning, which is crucial in a society like China, where independence is highly valued. 

Surgical Interventions, on the other hand, present more advanced treatment possibilities that are becoming more accessible due to technological advancements and improved surgical techniques. The rising incidence of neurodegenerative diseases in China, driven by lifestyle choices and the aging demographic, presents both challenges and opportunities for innovation across these treatment types.Overall, the segmentation within the China Neurodegenerative Disease Market underscores the importance of a multi-faceted approach in addressing these complex diseases, thus driving continued market momentum.

**Neurodegenerative Disease Market Route of Administration Insights**

The Route of Administration segment within the China Neurodegenerative Disease Market plays a crucial role in determining the effectiveness and patient adherence to treatments. Oral administration is widely favored due to its ease of use and acceptance among patients, contributing significantly to treatment compliance. Injectable routes, on the other hand, are important for delivering medications that require rapid onset, thus catering to acute symptoms associated with various neurodegenerative diseases.

Intravenous administration is also significant, particularly for patients requiring immediate medical interventions or high concentrations of therapeutics, allowing for controlled dosing and rapid absorption.Transdermal methods are gaining traction for their convenience and ability to maintain steady drug levels over time, minimizing the need for frequent dosing. 

As the prevalence of neurodegenerative diseases continues to rise in China, driven by an aging population, the selection of the appropriate route of administration is vital for optimizing therapeutic outcomes and improving patient quality of life. The diverse preferences in administration routes highlight the need for tailored approaches in treatment regimens, aiding healthcare professionals in managing these complex conditions effectively.Overall, understanding the dynamics of this segment is essential for stakeholders looking to innovate and expand their offerings within the China Neurodegenerative Disease Market.

**China Neurodegenerative Disease Market Key Players and Competitive Insights**

The China Neurodegenerative Disease Market is characterized by a rapidly evolving landscape that reflects the growing concern over neurological disorders such as Alzheimer's disease and Parkinson's disease. The competitive insights reveal a mix of established pharmaceutical companies and emerging players striving to capture market share through innovative treatment options and technologies. Manufacturers are leveraging advanced research methodologies and collaborative partnerships with research institutions to enhance their product offerings.

As the prevalence of neurodegenerative diseases continues to rise in China due to factors such as an aging population and lifestyle changes, companies are intensifying their efforts in clinical trials and product development to ensure that they remain at the forefront of this critical healthcare segment.

Mylan has established a significant presence in the China Neurodegenerative Disease Market, leveraging its strengths in generic and specialty pharmaceuticals. The company's extensive portfolio includes products that address various neurological conditions, making it a formidable competitor. Mylan's strengths lie in its strong distribution network, which facilitates the efficient delivery of medications throughout the country, as well as its commitment to affordability, which appeals to both healthcare providers and patients. Furthermore, Mylan's capability to conduct local clinical trials and its responsiveness to regulatory requirements in China enhance its competitive advantage.

The company's adaptability and focus on product accessibility resonate well within the market, reflecting a strategic alignment with the evolving needs of the Chinese population.Merck, on the other hand, holds a robust position in the China Neurodegenerative Disease Market with a diverse portfolio that includes innovative therapies and vaccines. 

The company is known for its commitment to research and development, focusing on cutting-edge treatments for neurodegenerative diseases that significantly improve patient outcomes. Key products in Merck's lineup cater to various neurological disorders, and its strong presence is bolstered by strategic partnerships and collaborations with local entities, enhancing its market footprint. Merck also benefits from its previous mergers and acquisitions aimed at strengthening its capabilities in neuroscience, allowing for a more comprehensive approach to treating neurodegenerative diseases in China.

The company's focus on innovation, coupled with its established reputation, positions Merck as a leading player that continues to make significant contributions to the advancement of treatments that address the growing healthcare needs in the region.

**Key Companies in the China Neurodegenerative Disease Market Include**

**China Neurodegenerative Disease Market Industry Developments**

In recent months, the China Neurodegenerative Disease Market has witnessed significant developments. Companies such as Mylan, Merck, Sanofi, AbbVie, Pfizer, Teva Pharmaceutical Industries, AstraZeneca, Johnson and Johnson, Novartis, Roche, Biogen, Eli Lilly, GSK, Amgen, and Boehringer Ingelheim are increasingly investing in research and development to address various neurodegenerative diseases, with an emphasis on innovative therapies such as gene therapy and monoclonal antibodies. Notably, in July 2023, Merck announced a strategic partnership with a local firm to enhance its Alzheimer’s treatment capabilities in China, catering to the country's growing elderly population. 

Additionally, in August 2023, Novartis disclosed an expansion of its manufacturing facility in China, which will facilitate an increase in production for neurodegenerative therapies. Over the past two to three years, the Chinese market has significantly expanded due to an aging population, with estimates suggesting a market valuation growth of over 20% since 2021. This growth reflects the increasing prevalence of neurodegenerative diseases, necessitating innovative solutions and stronger healthcare infrastructure across the country, backed by government initiatives to improve research funding and healthcare access.

**China Neurodegenerative Disease Market Segmentation Insights**

**Neurodegenerative Disease Market Disease Type****Outlook**

**Neurodegenerative Disease Market Diagnosis Method****Outlook**

**Neurodegenerative Disease Market Treatment Type****Outlook**

**Neurodegenerative Disease Market Route of Administration****Outlook**

## Market Drivers

### Rising Healthcare Expenditure

Rising healthcare expenditure in China is a significant driver for the neurodegenerative disease market. As the economy continues to grow, both public and private spending on healthcare is increasing, with a notable emphasis on [chronic disease management](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981). In 2025, healthcare spending is projected to reach approximately 7.5% of GDP, reflecting a commitment to improving health outcomes. This financial investment is likely to facilitate advancements in treatment options and enhance access to care for patients suffering from neurodegenerative disorders. Moreover, the expansion of health insurance coverage is expected to alleviate the financial burden on patients, thereby encouraging more individuals to seek timely diagnosis and treatment, which could further stimulate market growth.

### Increased Awareness and Education

Increased awareness and education regarding neurodegenerative diseases are vital drivers for the market in China. Public health campaigns and educational initiatives are fostering a better understanding of these conditions among healthcare professionals and the general population. As awareness grows, individuals are more likely to recognize symptoms early and seek medical advice, which can lead to timely diagnosis and treatment. This shift in public perception is crucial, as it not only empowers patients but also encourages investment in research and development. Furthermore, collaborations between healthcare providers and educational institutions are likely to enhance training for medical professionals, ensuring that they are equipped to manage neurodegenerative diseases effectively, thus supporting the overall growth of the neurodegenerative disease market.

### Government Initiatives and Funding

Government initiatives aimed at combating neurodegenerative diseases play a pivotal role in shaping the market landscape in China. Increased funding for research and development, alongside public health campaigns, is likely to enhance awareness and early diagnosis of these conditions. The Chinese government has allocated substantial resources to healthcare, with a focus on innovative treatments and preventive measures. For instance, the National Health Commission has launched programs to improve access to care for neurodegenerative diseases, which may lead to a more informed public and increased patient engagement. This proactive approach not only supports the neurodegenerative disease market but also fosters collaboration between public and private sectors, potentially accelerating the development of new therapies.

### Aging Population and Increased Incidence

An aging population in China is a critical driver for the neurodegenerative disease market. As life expectancy rises, the prevalence of age-related neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, is expected to increase significantly. Current estimates suggest that by 2030, approximately 25% of the population will be over 60 years old, leading to a surge in demand for diagnostic and therapeutic solutions. This demographic shift necessitates a robust healthcare infrastructure capable of addressing the needs of an aging society, thereby propelling growth in the neurodegenerative disease market. Furthermore, the economic burden associated with these diseases is substantial, with costs related to care and treatment projected to reach billions of dollars annually, highlighting the urgent need for effective interventions.

### Technological Innovations in Diagnostics

Technological innovations in diagnostics are transforming the neurodegenerative disease market in China. Advances in imaging techniques, biomarker discovery, and genetic testing are enabling earlier and more accurate diagnosis of neurodegenerative disorders. For instance, the integration of artificial intelligence in diagnostic tools is enhancing the ability to identify conditions at their onset, crucial for effective intervention. As these technologies become more accessible, they are likely to improve patient outcomes and reduce the overall burden of disease. The growing emphasis on precision medicine, supported by these innovations, may lead to tailored treatment approaches that cater to individual patient needs, thereby driving further growth in the neurodegenerative disease market.

## Future Outlook

The [Neurodegenerative Disease Market](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218) in China is projected to grow at a 7.6% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

**New opportunities:**

- Development of AI-driven diagnostic tools for early detection.
- Expansion of telehealth services for remote patient monitoring.
- Investment in personalized medicine approaches for tailored therapies.

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased healthcare investments.

## Segment Insights

### By Disease Type: Alzheimer's Disease (Largest) vs. Parkinson's Disease (Fastest-Growing)

In the China neurodegenerative disease market, Alzheimer's Disease represents the largest segment, capturing a significant share of the overall market. This is largely due to the aging population and increasing awareness regarding the diagnosis and treatment of the disease. On the other hand, Parkinson's Disease is rapidly gaining traction, reflecting a growing patient population and advancements in treatment options.

The growth trends for these disease types are influenced by multiple factors, including rising investment in research and development and an upsurge in healthcare spending. An increase in the prevalence of neurodegenerative conditions further emphasizes the need for innovative therapies. As a result, while Alzheimer's Disease remains dominant, Parkinson's Disease is expected to witness robust growth in the coming years, driven by technological advancements in medical treatment and early detection methods.

Alzheimer's Disease (Dominant) vs. Parkinson's Disease (Emerging)

Alzheimer's Disease has established itself as the dominant segment in the China neurodegenerative disease market, characterized by a high prevalence rate and substantial patient support initiatives. The ongoing development of drugs and therapies aimed at improving cognitive function is contributing to its strong market position. In contrast, Parkinson's Disease is emerging rapidly, fueled by increased awareness and recent breakthroughs in treatment options, which are enhancing the quality of life for patients. The growing body of clinical research is pivotal in the momentum of this segment, attracting both public and private funding to support innovative solutions and better disease management practices.

### By Diagnosis Method: Neurological Examination (Largest) vs. Imaging Techniques (Fastest-Growing)

The market share distribution for diagnosis methods reveals that Neurological Examination holds the largest share within this segment, as it forms a crucial part of initial assessments and evaluations of neurodegenerative disorders. Imaging Techniques are growing rapidly, gaining traction due to advancements in technology that enhance diagnostic capabilities. In contrast, Cerebrospinal Fluid Analysis and Electrophysiological Tests, while critical, represent smaller shares of the overall market.

Growth trends indicate a robust increase in the adoption of imaging techniques, driven by technological innovations and the increasing prevalence of neurodegenerative diseases among the aging population. Neurological Examination remains essential as it provides foundational insights that guide further diagnostic processes. The rise in awareness and emphasis on early diagnosis also propels the market forward, particularly for Imaging Techniques, which are quickly becoming preferred choices among healthcare professionals.

Neurological Examination: Dominant vs. Imaging Techniques: Emerging

Neurological Examination is characterized by its fundamental role in diagnosing neurodegenerative diseases, providing critical insights through clinical assessments and cognitive evaluations. This method serves as the first line of examination, making it indispensable in the overall diagnostic process. On the other hand, Imaging Techniques have emerged as significant competitors, enabled by advanced technologies such as MRI and PET scans that offer detailed visuals of brain structures and functions. This growing segment is seeing rapid adoption due to its effectiveness in identifying conditions at earlier stages, with the potential to enhance treatment outcomes. While Neurological Examination remains dominant in the market, the rising capabilities of Imaging Techniques positions them as a formidable emerging force thereby increasing competition and innovation in the China neurodegenerative disease market.

### By Treatment Type: Medication (Largest) vs. Therapy (Fastest-Growing)

In the China neurodegenerative disease market, the Treatment Type segment showcases a diverse array of options. Medication continues to dominate this landscape, holding the largest share, driven by the increasing prevalence of neurodegenerative disorders. Therapy and Rehabilitation options also contribute significantly but are growing at faster rates as healthcare shifts toward more holistic treatment approaches.

Emerging trends highlight the rapid development of innovative therapy techniques that enhance patient engagement and improve outcomes. Furthermore, advancements in rehabilitation methods are gaining traction, tapping into the growing demand for personalized care. These trends suggest a promising future for the segment, whereby both established and new treatment methodologies are expected to flourish as awareness and accessibility increase.

Medication (Dominant) vs. Rehabilitation (Emerging)

Medication remains the dominant player in the Treatment Type segment, characterized by a wide range of pharmaceutical options catering to a variety of neurodegenerative diseases. This segment benefits from extensive research and development efforts leading to new drug discoveries that directly address symptoms and disease progression. In contrast, Rehabilitation is emerging as a crucial aspect of long-term care strategies. This approach focuses on enhancing patients' quality of life through tailored programs that necessitate interdisciplinary collaboration. Rehabilitation techniques are evolving to incorporate advanced technologies and methodologies, thus attracting increased attention for investment and development. Together, these treatment modalities highlight a balancing act between traditional medication and innovative rehabilitation approaches that aim to redefine patient care.

### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing)

The 'Route of Administration' segment in the China neurodegenerative disease market exhibits a diverse distribution of shares among various methods. Oral administration holds the largest market share, favored for its ease of use and patient compliance. Conversely, the injectable route, while currently smaller, is gaining traction due to advancements in formulary technologies and increased interest in biologics, which are pivotal for treating complex neurodegenerative conditions.

Growth in this segment is primarily driven by the rising prevalence of neurodegenerative diseases in the population, along with increasing investments in research and development. The injectable route is emerging as the fastest-growing due to innovations that enhance drug delivery systems, making treatments more effective. Additionally, the convenience and potential for better therapeutic outcomes with injectable forms over traditional methods are fueling their adoption in clinical practice.

Oral (Dominant) vs. Injectable (Emerging)

Oral administration remains dominant in the China neurodegenerative disease market, characterized by its patient-friendly nature and established presence. These medications are often preferred for chronic conditions since they offer ease of administration and improved adherence. In contrast, the injectable segment is emerging, heavily influenced by recent advancements in drug formulations and delivery technologies. This method allows for targeted therapy with potentially enhanced efficacy, positioning it as a pivotal player in the treatment landscape. While oral forms dominate due to their long-standing use, the growing confidence in injectable therapies signifies a shift that could redefine treatment standards in neurodegenerative diseases.

## Competitive Benchmarking

The [neurodegenerative disease](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218)market is characterized by a rapidly evolving competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Key players such as Biogen (US), Eli Lilly (US), and Roche (CH) are strategically positioned to leverage advancements in biotechnology and personalized medicine. Biogen (US) focuses on developing novel therapies for Alzheimer's disease, while Eli Lilly (US) emphasizes its commitment to research and development in neurodegenerative disorders. Roche (CH) is enhancing its portfolio through strategic partnerships and acquisitions, thereby shaping a competitive environment that prioritizes innovation and patient-centric solutions.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Novartis (CH) and AstraZeneca (GB) is notable, as they engage in strategic collaborations to bolster their market presence and drive growth.
In October 2025, Biogen (US) announced a groundbreaking partnership with a leading AI firm to develop predictive models for Alzheimer's disease progression. This strategic move is likely to enhance Biogen's research capabilities, enabling the company to tailor therapies more effectively to patient needs. Such initiatives may position Biogen at the forefront of innovation in the neurodegenerative space, potentially leading to improved patient outcomes.
In September 2025, Eli Lilly (US) launched a new clinical trial for its investigational drug targeting early-stage Alzheimer's disease. This initiative underscores the company's focus on addressing unmet medical needs and highlights its commitment to advancing treatment options. The trial's outcomes could significantly influence Eli Lilly's market positioning and contribute to its long-term growth strategy.
In August 2025, Roche (CH) completed the acquisition of a biotech firm specializing in neuroinflammation, which is increasingly recognized as a critical factor in neurodegenerative diseases. This acquisition is expected to enhance Roche's research pipeline and expand its therapeutic offerings, thereby reinforcing its competitive edge in the market.
As of November 2025, current trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming increasingly vital, as companies collaborate to harness technological advancements and improve patient care. Looking ahead, competitive differentiation is likely to evolve, with a pronounced emphasis on innovation and technology rather than price-based competition. The focus on supply chain reliability and the development of cutting-edge therapies will be crucial in shaping the future landscape of the neurodegenerative disease market.

## Recent News & Developments

In recent months, the China Neurodegenerative Disease Market has witnessed significant developments. Companies such as Mylan, Merck, Sanofi, AbbVie, Pfizer, Teva Pharmaceutical Industries, AstraZeneca, Johnson and Johnson, Novartis, Roche, Biogen, Eli Lilly, GSK, Amgen, and Boehringer Ingelheim are increasingly investing in research and development to address various neurodegenerative diseases, with an emphasis on innovative therapies such as gene therapy and monoclonal antibodies. Notably, in July 2023, Merck announced a strategic partnership with a local firm to enhance its Alzheimer’s treatment capabilities in China, catering to the country's growing elderly population. 

Additionally, in August 2023, Novartis disclosed an expansion of its manufacturing facility in China, which will facilitate an increase in production for neurodegenerative therapies. Over the past two to three years, the Chinese market has significantly expanded due to an aging population, with estimates suggesting a market valuation growth of over 20% since 2021. This growth reflects the increasing prevalence of neurodegenerative diseases, necessitating innovative solutions and stronger healthcare infrastructure across the country, backed by government initiatives to improve research funding and healthcare access.

## Report Scope

| MARKET SIZE 2024 | 6.14(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.61(USD Billion) |
| MARKET SIZE 2035 | 13.76(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co (US), Amgen (US), Sanofi (FR), Pfizer (US) |
| Segments Covered | Disease Type, Diagnosis Method, Treatment Type, Route of Administration |
| Key Market Opportunities | Advancements in biomarker discovery enhance early diagnosis in the neurodegenerative disease market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in the neurodegenerative disease market amid regulatory shifts. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What was the overall market valuation of the China neurodegenerative disease market in 2024?**
A: The overall market valuation was $6.14 Billion in 2024.

**Q: What is the projected market valuation for the China neurodegenerative disease market by 2035?**
A: The projected valuation for 2035 is $13.76 Billion.

**Q: What is the expected CAGR for the China neurodegenerative disease market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 7.6%.

**Q: Which companies are considered key players in the China neurodegenerative disease market?**
A: Key players include Biogen, Eli Lilly, Roche, Novartis, AstraZeneca, Merck & Co, Amgen, Sanofi, and Pfizer.

**Q: What was the market valuation for Alzheimer's Disease in 2024?**
A: The market valuation for Alzheimer's Disease was $1.54 Billion in 2024.

**Q: What is the projected market size for Parkinson's Disease by 2035?**
A: The projected market size for Parkinson's Disease by 2035 is $2.78 Billion.

**Q: How much is the market for Multiple Sclerosis expected to grow by 2035?**
A: The market for Multiple Sclerosis is expected to grow to $2.05 Billion by 2035.

**Q: What are the main treatment types in the China neurodegenerative disease market?**
A: Main treatment types include Medication, Therapy, Rehabilitation, and Surgical Interventions.

**Q: What was the market size for Imaging Techniques in 2024?**
A: The market size for Imaging Techniques was $2.05 Billion in 2024.

**Q: What is the projected market size for the Transdermal route of administration by 2035?**
A: The projected market size for the Transdermal route of administration by 2035 is $5.03 Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-neurodegenerative-disease-market-52618*